Evotec SE (EVO) Non-Current Deffered Revenue (2020 - 2025)
Evotec SE (EVO) reported Non-Current Deffered Revenue of $169.2 million for Q4 2025, up 1.04% on a YoY basis from $167.4 million in Q4 2024, and up 1.04% sequentially from $167.4 million in Q4 2024.
Evotec SE (EVO) Non-Current Deffered Revenue (2020 - 2025) Analysis & Trends
Evotec SE (EVO) has 6 years of Non-Current Deffered Revenue data on file, last reported at $169.2 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deffered Revenue rose 1.04% year-over-year to $169.2 million; the trailing twelve-month figure through Dec 2025 stood at $169.2 million (up 1.04% YoY), and the FY2025 full-year result was $169.2 million, up 1.04% from the prior year.
- Non-Current Deffered Revenue improved to $169.2 million in Q4 2025, from $167.4 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $210.3 million in Q4 2022 to a low of -$205795.8 in Q2 2022.
- A 5-year average of $125.3 million and a median of $167.3 million in 2023 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue surged 449.18% in 2022 and dropped 20.56% in 2023, its largest moves.
- Tracing EVO's Non-Current Deffered Revenue over 5 years: stood at $38.3 million in 2021, then surged by 449.18% to $210.3 million in 2022, then declined by 20.56% to $167.1 million in 2023, then increased by 0.21% to $167.4 million in 2024, then climbed by 1.04% to $169.2 million in 2025.
- Business Quant data shows EVO's Non-Current Deffered Revenue at $169.2 million in Q4 2025, $167.4 million in Q4 2024, and $167.1 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 169.16 Mn |
| Dec 31, 2024 | 167.43 Mn |
| Dec 31, 2023 | 167.08 Mn |
| Dec 31, 2022 | 210.31 Mn |
| Jun 30, 2022 | -205,795.75 |
| Dec 31, 2021 | 38.30 Mn |
| Dec 31, 2020 | 26.75 Mn |